In a recent study published in Nature Immunology, researchers from UT Southwestern Medical Center have shed light on a critical mechanism through which cancer cells harness a hormone-receptor interaction to evade the immune system. The discovery unveils a potential target for novel cancer immunotherapy strategies and holds promise for addressing inflammatory and neurological disorders. Dr. Cheng Cheng “Alec” Zhang and his team elucidated how this hormone binding to receptors on myeloid cells can shift their function from tumor-fighting to tumor-supporting, thereby dampening the immune response.
Immunotherapies like immune checkpoint inhibitors, while groundbreaking, exhibit limited efficacy in only a subset of cancer patients, suggesting the complexity of immune evasion strategies employed by cancer cells. The researchers previously identified an inhibitory receptor, LILRB4, on myeloid cells that, when activated, impairs their anti-tumor activity. Expanding on this finding, they conducted a comprehensive search for proteins interacting with LILRB4, pinpointing SCG2 as a potent candidate. Through laboratory experiments, it was confirmed that SCG2 binds directly to LILRB4, triggering signaling cascades that stifle the tumor-targeting capabilities of myeloid cells and impede T cell recruitment for tumor destruction.
Furthermore, in mouse models engineered to express human LILRB4 and injected with SCG2-producing cancer cells, rapid tumor growth was observed. Treatment with an antibody blocking LILRB4 or removal of SCG2 effectively slowed cancer progression, emphasizing the therapeutic potential of disrupting the LILRB4-SCG2 interaction. This study underscores the intricate interplay between immune cells and cancer cells, offering insights into potential strategies for enhancing cancer immunotherapy and modulating immune responses in autoimmune or inflammatory conditions.
The research was supported by grants from various institutions, including the National Cancer Institute and the Cancer Prevention and Research Institute of Texas, highlighting the collaborative efforts driving innovative discoveries in cancer biology and immunotherapy. Moving forward, Dr. Zhang and his team aim to explore the translational implications of targeting the LILRB4-SCG2 axis for cancer treatment and investigate the therapeutic utility of manipulating this interaction in autoimmune disorders. By unraveling the molecular mechanisms underlying immune evasion in cancer, this study paves the way for precision immunotherapies tailored to disrupt cancer-promoting signals while bolstering anti-tumor immune responses.
Takeaways:
– Unveiling the role of hormone-receptor interactions in cancer immune evasion opens avenues for targeted immunotherapies.
– Disrupting the LILRB4-SCG2 axis presents a promising strategy to enhance anti-tumor immune responses.
– Collaborative research efforts supported by diverse funding sources drive advancements in cancer immunotherapy and precision medicine.
– Understanding the intricate interplay between immune cells and cancer cells is crucial for developing effective therapeutic interventions.
Tags: immunotherapy, exosomes
Read more on scitechdaily.com